A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®

This study has been terminated.
(See termination reason in detailed description.)
Information provided by:
ClinicalTrials.gov Identifier:
First received: July 24, 2006
Last updated: August 25, 2009
Last verified: January 2009
To compare efficacy and safety of Exubera® vs Humalog in patients with type 1 diabetes mellitus

Condition Intervention Phase
Diabetes Mellitus, Type 1
Drug: Inhaled Human Insulin (Exubera®)
Drug: Insulin lispro (Humalog)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 52-Week Multicenter, Open-Label, Randomized, Parallel, Two - Arm Study Comparing Exubera® (Inhaled Human Insulin) Vs. Humalog® (Insulin Lispro), Both In Combination With Insulin Glargine In Subjects With Type 1 Diabetes Mellitus

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Change From Baseline in Glycosylated Hemoglobin (HbA1c) Percent (%) [ Time Frame: At 52 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percentage of Subjects Who Attained HbA1c Levels of <8%, <7%, <6.5%, and >=8% [ Time Frame: At 52 weeks ] [ Designated as safety issue: No ]
  • Percentage of Subjects With Absolute Reduction in HbA1c Levels From Baseline of >0.5%, >0.7% and >1.0% [ Time Frame: At 52 weeks ] [ Designated as safety issue: No ]
  • Percentage of Subjects Who Attained Target Fasting Plasma Glucose (FPG) Values (4.0 to 6.5 mmol/l; 72 to 117 mg/dl) From Baseline [ Time Frame: At weeks 2, 4, 6, 12, 24, 36, and 52 or last observation. ] [ Designated as safety issue: No ]
  • Change From Baseline in FPG [ Time Frame: At 52 weeks or last observation ] [ Designated as safety issue: No ]
  • Change From Baseline in Fasting Blood Glucose Based on Glucometer Data and In-hospital Assessments [ Time Frame: To 52 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline in Post-prandial Blood Glucose Based on Glucometer Data and In-hospital Assessments [ Time Frame: To 52 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline in Insulin Antibody Levels [ Time Frame: At weeks 24 and 52 or last observation. ] [ Designated as safety issue: No ]
  • Change From Baseline in Body Weight [ Time Frame: At weeks 12, 24, 36, and 52 or last observation. ] [ Designated as safety issue: No ]
  • Change From Baseline in Body Mass Index [ Time Frame: At weeks 12, 24, 36, and 52 or last observation. ] [ Designated as safety issue: No ]
  • Change From Baseline in Basal Insulin Doses [ Time Frame: To 52 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline in Prandial Insulin Doses [ Time Frame: To 52 weeks ] [ Designated as safety issue: No ]
  • Blood Glucose Values From Baseline Determined by Home-monitored Blood Glucose (Subject Recorded Worksheet Values) [ Time Frame: To 52 weeks. ] [ Designated as safety issue: No ]
  • Change in Fasting Lipids From Baseline [ Time Frame: At weeks 24 and 52 or last observation ] [ Designated as safety issue: No ]

Enrollment: 58
Study Start Date: November 2006
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Control Drug: Insulin lispro (Humalog)
Subcutaneous insulin regimen of pre-prandial insulin lispro and administration of insulin glargine QD.
Experimental: Experimental Drug: Inhaled Human Insulin (Exubera®)
Preprandial inhaled insulin regimen and administration of insulin glargine QD

Detailed Description:
Pfizer announced in October 2007 that it would stop marketing Exubera®. At that time recruitment for study, A2171035 was placed on hold. Nektar, the company from which Pfizer licensed Exubera®, announced on April 9, 2008 that it had stopped its search for a new marketing partner. Accordingly, there will be no commercial availability of Exubera®. As a result, study A2171035 was terminated on May 12, 2008. Neither safety nor efficacy reasons were the cause of the study termination.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diabetes mellitus Type 1

Exclusion Criteria:

  • Severe Asthma, severe Chronic Obstructive Pulmonary Disease (COPD)
  • Smoking
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00356421

United States, New Jersey
Pfizer Investigational Site
Hamilton, New Jersey, United States, 08610
Pfizer Investigational Site
New Brunswick, New Jersey, United States, 08903
Pfizer Investigational Site
Vienna, Austria, A-1030
Pfizer Investigational Site
Vienna, Austria, A-1130
Pfizer Investigational Site
Edegem, Belgium, 2650
Pfizer Investigational Site
Genk, Belgium, 3600
Pfizer Investigational Site
Leuven, Belgium, 3000
Pfizer Investigational Site
Aarhus, Denmark, 8000
Pfizer Investigational Site
Kuopio, Finland, 70211
Pfizer Investigational Site
Brest CEDEX, France, 29609
Pfizer Investigational Site
Corbeil Essonnes Cedex, France, 91106
Pfizer Investigational Site
Strasbourg Cedex, France, 67091
Pfizer Investigational Site
Waterford, Ireland
Pfizer Investigational Site
Amsterdam, Netherlands, NL-1105 AZ
Pfizer Investigational Site
Stavanger, Norway, 4095
Pfizer Investigational Site
Lisboa, Portugal, 1349-019
Pfizer Investigational Site
Las Palmas, Las Palmas de Gran Canaria, Spain, 35016
Pfizer Investigational Site
Valencia, Spain, 46010
Pfizer Investigational Site
Stockholm, Sweden, 171 76
Pfizer Investigational Site
Stockholm, Sweden, 182 88
United Kingdom
Pfizer Investigational Site
Bournemouth, Dorset, United Kingdom, BH7 7DW
Pfizer Investigational Site
Dundee, Tayside, United Kingdom, DD1 9SY
Pfizer Investigational Site
Birmingham, West Midlands, United Kingdom, B9 5SS
Sponsors and Collaborators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00356421     History of Changes
Other Study ID Numbers: A2171035
Study First Received: July 24, 2006
Results First Received: June 24, 2009
Last Updated: August 25, 2009
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Autoimmune Diseases
Endocrine System Diseases
Glucose Metabolism Disorders
Immune System Diseases
Metabolic Diseases
Insulin Lispro
Insulin, Globin Zinc
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on November 27, 2015